Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy

被引:10
|
作者
Park, Hanla A. [1 ,2 ]
Seibold, Petra [1 ]
Edelmann, Dominic [3 ]
Benner, Axel [3 ]
Canzian, Federico [4 ]
Alwers, Elizabeth [5 ]
Jansen, Lina [5 ]
Schneider, Martin [6 ]
Hoffmeister, Michael [5 ]
Brenner, Hermann [5 ,7 ,8 ,9 ]
Chang-Claude, Jenny [1 ,10 ]
机构
[1] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany
[2] Heidelberg Univ, Med Fac, Heidelberg, Germany
[3] German Canc Res Ctr, Div Biostat, Heidelberg, Germany
[4] German Canc Res Ctr, Genom Epidemiol Grp, Heidelberg, Germany
[5] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany
[6] Heidelberg Univ, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany
[7] German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany
[8] Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[9] German Canc Res Ctr, Country German Canc Consortium DKTK, Heidelberg, Germany
[10] Univ Med Ctr Hamburg Eppendorf, Univ Canc Ctr Hamburg, Canc Epidemiol Grp, Hamburg, Germany
关键词
GLUTATHIONE-S-TRANSFERASE; IMMUNOGENIC CELL-DEATH; KRAS MUTATIONAL STATUS; DNA-REPAIR GENES; PREDICTIVE MARKERS; EXCISION-REPAIR; POLYMORPHISMS; EXPRESSION; BEVACIZUMAB; RESISTANCE;
D O I
10.1158/1055-9965.EPI-21-0814
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Associations between candidate genetic variants and treatment outcomes of oxaliplatin, a drug commonly used for colorectal cancer patients, have been reported but not robustly established. This study aimed to validate previously reported prognostic and predictive genetic markers for oxaliplatin treatment outcomes and evaluate additional putative functional variants. Methods: Fifty-three SNPs were selected based on previous reports (40 SNPs) or putative function in candidate genes (13 SNPs). We used data from 1,502 patients with stage II-IV colorectal cancer who received primary adjuvant chemotherapy, 37% of whom received oxaliplatin treatment. Multivariable Cox proportional hazards models for overall survival and progression-free survival were applied separately in stage II-III and stage IV patients. For predictive SNPs, differential outcomes according to the type of chemotherapy (oxaliplatin-based vs. others) were evaluated using an interaction term. For prognostic SNPs, the association was assessed solely in patients with oxaliplatin-based treatment. Results: Twelve SNPs were predictive and/or prognostic at P < 0.05 with differential survival based on the type of treatment, in patients with stage II-III (GSTM5-rs11807, ERCC2-rs13181, ERCC2-rs1799793, ERCC5-rs2016073, XPC-rs2228000, P2RX7-rs208294, HMGB1-rs1360485) and in patients with stage IV (GSTM5-rs11807, MNAT1-rs3783819, MNAT1-rs4151330, CXCR1-rs2234671, VEGFA-rs833061, P2RX7-rs2234671). In addition, five novel putative functional SNPs were identified to be predictive (ATP8B3-rs7250872, P2RX7-rs2230911, RPA1-rs5030755, MGMT-rs12917, P2RX7-rs2227963). Conclusions: Some SNPs yielded prognostic and/or predictive associations significant at P < 0.05, however, none of the associations remained significant after correction for multiple testing. Impact: We did not robustly confirm previously reported SNPs despite some suggestive findings but identified further potential predictive SNPs, which warrant further investigation in well-powered studies.
引用
收藏
页码:352 / 361
页数:10
相关论文
共 50 条
  • [1] Validation of genetic markers for prognosis in colon cancer patients treated with oxaliplatin-based chemotherapy
    Park, Hanla
    Seibold, Petra
    Edelmann, Dominic
    Benner, Axel
    Jansen, Lina
    Canzian, Federico
    Schneider, Martin
    Hoffmeister, Michael
    Brenner, Hermann
    Chang-Claude, Jenny
    GENETIC EPIDEMIOLOGY, 2020, 44 (05) : 509 - 509
  • [2] Sarcoidosis Associated with Oxaliplatin-Based Chemotherapy for Colorectal Cancer
    Choi, Ji Hoon
    Shin, Jung A.
    Park, Hye Kyeong
    Kim, Su Young
    Jung, Hoon
    Lee, Sung-Soon
    Lee, Hye Ran
    Koo, Hyeon-Kyoung
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2014, 2014
  • [3] Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy
    Bahrami, Afsane
    Amerizadeh, Forouzan
    Hassanian, Seyed Mahdi
    ShahidSales, Soodabeh
    Khazaei, Majid
    Maftouh, Mina
    Ghayour-Mobarhan, Majid
    Ferns, Gordon A.
    Avan, Amir
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (03) : 2193 - 2201
  • [4] Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy
    L Paré-Brunet
    A Sebio
    J Salazar
    A Berenguer-Llergo
    E Río
    A Barnadas
    M Baiget
    D Páez
    The Pharmacogenomics Journal, 2015, 15 : 397 - 404
  • [5] Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy
    Pare-Brunet, L.
    Sebio, A.
    Salazar, J.
    Berenguer-Llergo, A.
    Rio, E.
    Barnadas, A.
    Baiget, M.
    Paez, D.
    PHARMACOGENOMICS JOURNAL, 2015, 15 (05): : 397 - 404
  • [6] Oxaliplatin-based chemotherapy in the management of colorectal cancer
    Capdevila, Jaume
    Elez, Elena
    Peralta, Sergio
    Macarulla, Teresa
    Javier Ramos, Francisco
    Tabernero, Josep
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (08) : 1223 - 1236
  • [7] Genetic variants in RPA1 associated with the response to oxaliplatin-based chemotherapy in colorectal cancer
    Shuwei Li
    Kaili Xu
    Dongying Gu
    Lei He
    Lisheng Xie
    Zhengxin Chen
    Zhimin Fan
    Lingjun Zhu
    Mulong Du
    Haiyan Chu
    Zhengdong Zhang
    Yuan Wu
    Min Ni
    Meilin Wang
    Journal of Gastroenterology, 2019, 54 : 939 - 949
  • [8] Genetic variants in RPA1 associated with the response to oxaliplatin-based chemotherapy in colorectal cancer
    Li, Shuwei
    Xu, Kaili
    Gu, Dongying
    He, Lei
    Xie, Lisheng
    Chen, Zhengxin
    Fan, Zhimin
    Zhu, Lingjun
    Du, Mulong
    Chu, Haiyan
    Zhang, Zhengdong
    Wu, Yuan
    Ni, Min
    Wang, Meilin
    JOURNAL OF GASTROENTEROLOGY, 2019, 54 (11) : 939 - 949
  • [9] Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer
    Beatty, Gregory L.
    Giantonio, Bruce J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (05) : 683 - 688
  • [10] Outcomes in patients (pts) with colorectal cancer (CRC) treated with oxaliplatin-based chemotherapy (OC) following prior oxaliplatin exposure
    Bhadkamkar, Nishin Anil
    Sahin, Ibrahim Halil
    Shen, Yehua
    Hassabo, Hesham Mohamed
    Kee, Bryan K.
    Hassan, Manal
    Garrett, Chris R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)